Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK/Adolor's Entereg Eligible For Approval, But Lacks Proper Risk Management Plan, Advisory Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Entereg NDA has Feb. 10 user fee date for gastrointestinal recovery after bowel resection surgery.

You may also be interested in...



Entereg Documents Offer Detailed Insight Into REMS Review Process

GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.

Entereg Documents Offer Detailed Insight Into REMS Review Process

GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.

Adolor/GSK’s Entereg Approved By FDA

Cleared at last, hospital constipation drug brings risk management plan.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel